SAB Biotherapeutics, Inc. (SABS) stock
SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.96−0.12 (-3.90%)
Close on Nov 13, 2026Market cap $269.32MP/E –Yield –
SAB Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
SAB Biotherapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $58.38M, up 86.6% year over year. For fiscal 2025 it was $34.35M, up 13.6% from the year before. The highest annual figure on record is $57.18M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.35M | +13.6% |
| FY2024 | Dec 31, 2024 | $30.25M | +83.2% |
| FY2023 | Dec 31, 2023 | $16.52M | -54.7% |
| FY2022 | Dec 31, 2022 | $36.44M | -36.3% |
| FY2021 | Dec 31, 2021 | $57.18M | +104.9% |
| FY2020 | Dec 31, 2020 | $27.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.08M | +101.5% |
| Q2 FY2026 | Jun 30, 2026 | $16.17M | +131.1% |
| Q1 FY2026 | Mar 31, 2026 | $13.40M | +75.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.73M | +40.2% |
| Q3 FY2025 | Sep 30, 2025 | $8.97M | +14.5% |
| Q2 FY2025 | Jun 30, 2025 | $7.00M | +2.6% |
| Q1 FY2025 | Mar 31, 2025 | $7.66M | -6.0% |
| Q4 FY2024 | Dec 31, 2024 | $7.65M | +78.1% |
| Q3 FY2024 | Sep 30, 2024 | $7.83M | +94.8% |
| Q2 FY2024 | Jun 30, 2024 | $6.82M | +86.3% |
| Q1 FY2024 | Mar 31, 2024 | $8.15M | +79.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.30M | -39.8% |
| Q3 FY2023 | Sep 30, 2023 | $4.02M | -45.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.66M | -57.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.54M | -66.0% |
| Q4 FY2022 | Dec 31, 2022 | $7.14M | -33.0% |
| Q3 FY2022 | Sep 30, 2022 | $7.35M | -51.2% |
| Q2 FY2022 | Jun 30, 2022 | $8.58M | -54.1% |
| Q1 FY2022 | Mar 31, 2022 | $13.32M | +4.2% |
| Q4 FY2021 | Dec 31, 2021 | $10.65M | – |
| Q3 FY2021 | Sep 30, 2021 | $15.07M | – |
| Q2 FY2021 | Jun 30, 2021 | $18.68M | – |
| Q1 FY2021 | Mar 31, 2021 | $12.78M | – |
See a number that looks wrong?